Dateline City: KENILWORTH, N.J. Submission Based on PAOLA-1 Trial Which Studied LYNPARZA with Bevacizumab in…
.jpg)
A national audit shows that only one in four men with advanced prostate cancer receives…
Dateline City: KENILWORTH, N.J. KEYTRUDA Is the First Anti-PD-1 Therapy Approved for Certain Patients With…
Dateline City: KENILWORTH, N.J. Phase 3 KEYNOTE-604 Study Did Not Meet Other Dual Primary Endpoint…
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Dateline City: KENILWORTH, N.J. LYNPARZA Reduced the Risk of Disease Progression or Death by 47%…
Dateline City: KENILWORTH, N.J. KEYTRUDA Now Approved for Six Cancer Types Plus Microsatellite Instability-High (MSI-H)…
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE:MRK), known as MSD outside the United States…
Dateline City: KENILWORTH, N.J. Oncologic Drugs Advisory Committee Voted That LYNPARZA Demonstrated a Favorable Benefit-Risk…
Dateline City: KENILWORTH, N.J. New Findings from Phase 3 KEYNOTE-042 Study Were Presented Today at…
Dateline City: KENILWORTH, N.J. & BURLINGTON, Mass. Acquisition Further Diversifies Merck’s Oncology Pipeline with Expansion…
Dateline City: KENILWORTH, N.J. AstraZeneca and Merck’s LYNPARZA Reduced the Risk of Disease Progression or…
Dateline City: KENILWORTH, N.J. Application Based on Results from Phase 2 KEYNOTE-057 Trial, to be…
Dateline City: KENILWORTH, N.J. KEYTRUDA is the First Anti-PD-1 Therapy Approved in Europe for the…